Genovis AB (publ.) (FRA:5GV)

Market Cap	122.98M -13.6%
Revenue (ttm)	12.37M +11.2%
Net Income	1.85M -24.0%
EPS	0.03 -24.8%
Shares Out	n/a
PE Ratio	66.44
Forward PE	55.14
Dividend	n/a
Ex-Dividend Date	n/a

Volume	300
Open	1.764
Previous Close	1.752
Day's Range	1.764 - 1.764
52-Week Range	1.414 - 2.235
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 10, 2026

About Genovis AB (publ.)

Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOUS (SpeB), a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. It also offers GlySERIAS, an enzyme that digests flexible glycine-rich fusion protein linkers; GlyCLICK, a conjugation technology; TransGLYCIT, a platform technology; and GingisRE...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 42
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 5GV

Financial Performance

In 2025, Genovis AB (publ.)'s revenue was 129.93 million, a decrease of -1.06% compared to the previous year's 131.32 million. Earnings were 23.50 million, a decrease of -28.61%.

Financial numbers in SEK

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 27, 2026

Data Sources Report a data error